Core Viewpoint - Neuphoria Therapeutics Inc. is urging shareholders to vote for its director nominees on the WHITE proxy card, following a recommendation from Institutional Shareholders Services (ISS) that supports the company's management against a proxy contest initiated by Lynx1 Capital Management [1][2][3] Group 1: Company Overview - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders [7] - The company is advancing its lead drug candidate, BNC210, which is designed to treat post-traumatic stress disorder (PTSD) and is characterized as a first-of-its-kind anti-anxiety therapeutic [7] - Following the Phase 3 clinical trial results announced on October 20, 2025, which missed primary and secondary endpoints, Neuphoria has halted development of BNC210 for social anxiety disorder and is conducting a strategic review [7] Group 2: Proxy Contest and ISS Recommendation - ISS has recommended that Neuphoria shareholders vote FOR both of the company's director nominees, Peter Miles Davies and David Wilson, and WITHHOLD votes for the dissident nominees from Lynx1 Capital Management [2][3] - The ISS report highlighted that the dissident has not presented a compelling case for change, thus supporting the management's nominees [3] - Neuphoria's board has been proactive in raising capital ahead of the Phase 3 trial data readout, strengthening the company's balance sheet as it proceeds with a strategic review [6]

Core Viewpoint - Neuphoria Therapeutics Inc. urges shareholders to vote for its director nominees as recommended by Institutional Shareholders Services (ISS), emphasizing the board's proactive actions and strategic review process to maximize shareholder value [1][2][3]. Company Overview - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders, with its lead drug candidate BNC210 aimed at treating post-traumatic stress disorder (PTSD) [7]. - The company has halted the development of BNC210 for social anxiety disorder following a Phase 3 clinical trial that missed its primary and secondary endpoints [7]. Proxy Contest - ISS has recommended that shareholders vote for Neuphoria's director nominees, Peter Miles Davies and David Wilson, while withholding votes for the dissident nominees from Lynx1 Capital Management [1][3]. - The board's actions in response to the clinical trial results and the dissident's offer have been deemed appropriate, with a commitment to transparency and shareholder updates [6]. Strategic Review - Neuphoria's board is conducting a strategic review to explore alternatives that could provide maximum value to shareholders, which includes inviting the dissident to participate under similar terms as other parties [6]. - The company has raised capital proactively ahead of the Phase 3 trial data readout, strengthening its balance sheet for the ongoing strategic review [6].

Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the f ...

Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the f ...

Core Viewpoint - Neuphoria Therapeutics Inc. is addressing what it perceives as a deceptive campaign by Lynx1 Master Fund LP aimed at distracting shareholders from Lynx1's own shortcomings and lack of a clear plan [1][2][3] Company Positioning - Neuphoria emphasizes its commitment to transparency and value creation, urging stockholders to support its nominees while withholding votes for Lynx1's nominees [2][8] - The company is focused on developing therapies for neuropsychiatric disorders, with its lead drug candidate BNC210 targeting PTSD [9] Response to Lynx1's Claims - Neuphoria refutes Lynx1's assertions, presenting a detailed counterargument to each claim made by Lynx1, highlighting the company's strategic actions and board qualifications [4][5][6][7] - The company asserts that Lynx1's nominees lack the necessary experience and understanding of the company's needs, particularly in neuropsychiatric disorders [5][7] Strategic Review and Clinical Trials - Following the AFFIRM-1 Phase 3 clinical trial results, which missed primary and secondary endpoints, Neuphoria has halted development of BNC210 for social anxiety disorder and is conducting a strategic review [9] - The company is also engaged in partnerships, including one with Merck, to advance its pipeline for treating cognitive deficits in Alzheimer's disease [9] Board Composition and Governance - Neuphoria defends its current board's qualifications and experience, contrasting them with Lynx1's nominees, who are portrayed as lacking relevant expertise [6][7] - The company emphasizes the importance of having a strong cash balance and strategic oversight in navigating its clinical trials and corporate governance [6][7]

Core Viewpoint - Neuphoria Therapeutics Inc. is urging stockholders to vote for its two nominees for the Board of Directors, emphasizing their qualifications and the importance of stability during the ongoing strategic review process [1][2][4]. Group 1: Board Nominees and Voting - Neuphoria is advocating for stockholders to vote "FOR" its nominees, Peter Miles Davies and David Wilson, who possess significant expertise in investment and capital allocation relevant to the company's strategic review [2][8]. - A dissident stockholder, Lynx1 Master Fund LP, has nominated its own candidates, and Neuphoria is urging stockholders to vote "WITHHOLD" on these nominees [3][12]. - The company emphasizes that introducing inexperienced directors could disrupt the strategic review process and negatively impact value creation [11][13]. Group 2: Strategic Review Process - Neuphoria's Board is committed to maximizing value for all stockholders and is conducting a comprehensive review of strategic alternatives with the help of independent financial and legal advisors [4][6]. - The strategic review process is ongoing, with H.C. Wainwright & Co. serving as the financial advisor, and the Board is evaluating various proposals from interested parties [6][7]. - The company believes that maintaining continuity on the Board is critical to successfully completing the strategic review and maximizing value [8][21]. Group 3: Financial Position and Pipeline - Neuphoria has raised capital through its at-the-market program to ensure a strong financial position ahead of anticipated clinical data readouts, which is crucial for negotiating favorable terms with investors [15][16]. - Following a negative data readout from the AFFIRM-1 Phase 3 trial, the company is focused on exploring strategic alternatives and pursuing other pipeline programs [16][24]. - The company’s financial preparedness enhances its credibility and ability to attract high-quality strategic opportunities, thereby maximizing long-term stockholder value [18][20].

Core Viewpoint - Neuphoria Therapeutics Inc. is exploring strategic alternatives to enhance its pipeline and maximize stockholder value, including potential mergers, acquisitions, and partnerships [2][3][5]. Strategic Alternatives - The company has engaged H.C. Wainwright & Co. as its exclusive financial advisor to assist in evaluating strategic options [3]. - There is no defined timeline for this exploration, and the company does not guarantee that any strategic alternatives will be finalized [3]. Unsolicited Offer - On November 10, 2025, Neuphoria received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP to acquire all outstanding shares for $5.20 per share in cash [4]. - Lynx1 Master Fund LP also intends to nominate individuals for election to Neuphoria's Board of Directors at the upcoming Annual Meeting [4]. Board of Directors' Response - Neuphoria's Board is committed to acting in the best interests of all stockholders and will evaluate the unsolicited offer in conjunction with its strategic alternatives review [5]. - The Board will present its recommendations regarding director nominees in the proxy statement for the 2025 Annual Meeting [6]. Annual Meeting Details - The 2025 Annual Meeting is scheduled for December 12, 2025, with a record date of October 15, 2025 [6]. - Stockholders are not required to take any action at this time [7]. Company Overview - Neuphoria is a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders [9]. - The company previously advanced its lead drug candidate, BNC210, for social anxiety disorder and PTSD but halted its development following unsuccessful clinical trial results [9]. - Neuphoria has a partnership with Merck & Co. for two drugs in early-stage clinical trials targeting cognitive deficits in Alzheimer's disease [9].

Company Performance - Neuphoria Therapeutics Inc. (NASDAQ:NEUP) experienced a significant stock price drop of 67.18%, closing at $5.05, due to the failure of its AFFIRM-1 Phase 3 trial for BNC210, which did not meet its primary and secondary endpoints. The company plans to conduct a strategic review of its portfolio and operations [1] - AlphaVest Acquisition Corp Unit (NASDAQ:ATMVU) saw a 41.05% decline in its stock price to $12.97, potentially linked to investor sentiment surrounding its merger agreement with AMC Corporation, highlighting the speculative nature of SPACs [2] - Cycurion, Inc. (NASDAQ:CYCU) faced a 34.51% decrease in stock price to $0.16 after receiving a Delisting Determination Letter from Nasdaq, indicating challenges ahead for the company and impacting investor confidence [3] - SMX (Security Matters) Public Limited Company (SMX) experienced a 32.03% decline in stock price to $0.78, with market performance possibly reacting to undisclosed operational updates or industry trends [4] - American Rebel Holdings, Inc. (NASDAQ:AREB) saw a 29.91% reduction in stock price to $1.31, despite securing a distribution placement for its American Rebel Light Beer, indicating broader economic factors affecting consumer cyclical sectors [5] Market Trends - Recent market movements illustrate the volatile nature of stock prices, influenced by company-specific news, industry trends, and broader economic conditions, prompting investors and stakeholders to adjust their strategies accordingly [6]

Core Insights - Neuphoria Therapeutics Inc. announced that the AFFIRM-1 Phase 3 trial of BNC210 for social anxiety disorder did not meet its primary or secondary endpoints [1][3] - The company plans to conduct a strategic review of its portfolio and operations to maximize shareholder value [2][3] Trial Results - The AFFIRM-1 trial did not show statistically significant changes in the primary endpoint, which was the change in Subjective Units of Distress Scale (SUDS) scores during a public speaking challenge [1][6] - Secondary endpoints also failed to demonstrate significant differences, although the safety and tolerability profile of BNC210 remained favorable [1][3] Strategic Actions - Following the trial results, Neuphoria will discontinue the development of its social anxiety disorder program [3] - The company will evaluate further development of BNC210 for post-traumatic stress disorder (PTSD) based on previous positive data [3] Financial Position - As of June 30, 2025, Neuphoria had cash and cash equivalents of $14.2 million, which is expected to fund operations through the second fiscal quarter of 2027 [5] Partnerships - Neuphoria has an ongoing partnership with Merck for the development of MK-1167, which is currently in a Phase 2 trial for Alzheimer's disease [4][7] - The partnership with Merck could yield up to $450 million in milestone payments and royalties on net sales of licensed medicines [4]

Core Insights - Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders, with a lead drug candidate BNC210 targeting social anxiety disorder and post-traumatic stress disorder [2][4] Company Overview - Neuphoria is advancing BNC210, an oral selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, designed for acute and chronic treatment of anxiety disorders [2] - The company has a strategic partnership with Merck & Co., Inc. for two drugs in early-stage clinical trials aimed at cognitive deficits in Alzheimer's disease and other CNS conditions [2] - Neuphoria's pipeline includes next-generation α7 nicotinic acetylcholine receptor programs and Kv3.1/3.2 preclinical programs, both in lead optimization development [2] Upcoming Events - Neuphoria will present a pharmacokinetic/pharmacodynamic analysis of the BNC210 Attune Phase 2b dataset at the ASCP 2025 Annual Meeting, scheduled for May 28, 2025 [4]